Oral Montelukast Reduces Risk of Diabetic Retinopathy: ARVO 2021
Chronic inflammation and oxidative stress are critical components in the pathogenic cascade of early diabetic retinopathy, characterized by neuronal and vascular degeneration. In a recent study, researchers have found that oral montelukast decreases the odds of diabetic retinopathy (DR). The study findings were presented at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) on May 2, 2021.
Recent research using experimental animal models has suggested that montelukast, a leukotriene receptor antagonist, may play a role in preventing diabetic retinopathy (DR). However, few studies have investigated its potential efficacy in humans. Therefore, researchers of the Byers Eye Institute at Stanford, USA, conducted a study to investigate whether the use of oral montelukast was associated with decreased odds of DR in patients with diabetes mellitus.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.